QIAGEN announced that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the bone marrow do not mature and become healthy blood cells.
On Jan. 22, 2018, Sanofi announce that it has entered into a definitive agreement to acquire all outstanding shares of Bioverativ, the hemophilia and blood disorders-focused spin-off company of Biogen, for $105 per share, or a transaction value of approximately $11.6 billion. The transaction was unanimously approved by the boards of directors of Sanofi and Bioverativ.
Accelerate@Babraham is designed to support the earliest stages of new life-science ventures, by providing easy-access laboratory and office space, (the ‘bio-incubator’) together with supporting programmes of business, science, finance and entrepreneurial mentoring (the ‘accelerator’) provided by strategic partners.
The ETC (Emerging Technology Centers), Baltimore City’s award-winning technology and innovation centers, announces the Accelerate Baltimore (AB) program will run for its seventh consecutive year and applications are now open. The ETC will select six tech startups for the 13-week program set to begin mid-March. The Abell Foundation has awarded ETC $250,000 in funding for this seed accelerator for the third year in a row. Based on the model of last year’s successful program, each of this year’s AB winners will be awarded $25,000 in seed stage funding, while one company will be awarded an additional $100,000 in follow on funding at the end of the program.
Richard Hughen’s first entrepreneurial experience was as Managing Director at e-learning startup LearnWare, where he says his “addiction” to startups began in earnest. The former manager at Abbott Diagnostics, Cordis and Johnson & Johnson enjoyed LearnWare for the very reason that entrepreneurs usually get hooked: building something from scratch is exhilarating
California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today commended the U.S. Senate’s confirmation of Alex M. Azar, II as the new secretary of the U.S. Department of Health and Human Services (HHS).
Paragon Bioservices has plans to expand to new space over the next two years to help companies develop and manufacture biopharmaceuticals.
Researchers with the Johns Hopkins University School of Medicine developed a new blood test able to screen for eight types of cancers.
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an agreement with FUJIFILM Diosynth Biotechnologies (FUJIFILM) for the manufacture of REGENXBIO’s lead product candidates, including RGX-314 and RGX-501, which will support late-stage clinical development and early commercialization. This partnership builds on the foundation of REGENXBIO’s internal manufacturing and process development capabilities.
New York City is doubling down on its long-discussed, never-realized dream of building a biotech hub to rival South San Francisco and Boston. The latest iteration of the dream comes backed by a $500 million financing package and a goal to quadruple the amount of R&D space in the city.
